



August 31, 2015

TransEnterix, Inc. Names Paul Ziegler as Vice President of Sales

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced that Paul Ziegler has been named Vice President of Sales, effective August 31, 2015. Mr. Ziegler will report directly to TransEnterix's CEO Todd M. Pope.

"We are thrilled to have Paul join the TransEnterix team. He brings a tremendous amount of highly relevant commercial leadership experience, from developing and implementing a successful sales strategy through managing a large and growing robotic sales force," said Todd M. Pope, Chief Executive Officer of TransEnterix. "It was important to us to bring someone on board who has an in-depth knowledge of the surgical robotics industry to lead our sales efforts. Paul's background and experience will be invaluable as we prepare to launch the SurgiBot next year."

Mr. Ziegler joins TransEnterix with over a decade of medical device sales experience, having spent the majority of that time managing capital and clinical sales in the surgical robotics industry. Most recently, he served as Regional Vice President of Sales at Intuitive Surgical, Inc., where he was responsible for developing and delivering the company's sales strategy for robotically-assisted minimally invasive surgical products in the western United States. Mr. Ziegler's experience while at Intuitive also included successfully building and implementing a sales force infrastructure, managing a nation-wide sales division and effectively expanding sales teams during periods of rapid growth. Prior to joining Intuitive, Mr. Ziegler held sales management positions at Johnson & Johnson and Dianon Systems. Mr. Ziegler is a veteran of the armed forces, having served in the United States Navy for eight years.

"Based on my last 9 years in the robotic surgery space, I am extremely enthusiastic about the reception of the SurgiBot System in the surgical community. I believe that surgeons will value the ability to remain patient-side within the sterile field while utilizing a system that mimics familiar laparoscopic techniques," said Ziegler. "I am very excited to be joining the TransEnterix team and am looking forward to building a world class commercial organization."

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery by addressing the economic and clinical challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a robotically enhanced laparoscopic surgical platform that allows the surgeon to be patient-side within the sterile field. For more information, visit the company's website at www.transenterix.com.

About SurgiBot

The [SurgiBot](#) system, currently in development, is a minimally invasive, patient-side robotic surgery system. The system utilizes [flexible instruments](#) through articulating channels controlled directly by the surgeon, with robotic assistance, at the patient's bedside. The flexible nature of the system allows for multiple instruments to be introduced and deployed through a single incision. The SurgiBot System has not been cleared by the FDA for use in the United States.

Forward Looking Statements

This press release includes statements relating to the SurgiBot System, and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations, including whether Mr. Ziegler's background and experience will prove to be invaluable as we prepare to launch SurgiBot next year, Factors that could cause our results to differ materially from those described include, but are not limited to, whether the SurgiBot System's 510(k) application will be cleared by the U.S. FDA. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2014 filed on February 20, 2015, our Form 10-Q for the 2015 second quarter filed on August 6, 2015, and other filings we make with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement,

whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20150831005374/en/>

Westwicke Partners

Investor Contact:

Mark Klausner, 443-213-0501

transenterix@westwicke.com

or

TransEnterix, Inc.

Media Contact:

Mohan Nathan, 919-917-6559

mnathan@transenterix.com

Source: TransEnterix, Inc.

News Provided by Acquire Media